irradiated Flt3L-expressing B16-F10 tumor cell vaccine

The irradiated Flt3L-expressing B16-F10 tumor cell vaccine (also known as Fl3vax or B16-Flt3L vaccine) is a preclinical, cell-based cancer immunotherapy used primarily in murine melanoma models. It consists of B16-F10 melanoma cells that have been stably transduced with a retroviral vector to express Fms-like tyrosine kinase 3 ligand (Flt3L), a hematopoietic cytokine, and then lethally irradiated to prevent proliferation while maintaining metabolic activity. The vaccine's mechanism of action relies on the continuous secretion of Flt3L, which promotes the survival, differentiation, maturation, and expansion of dendritic cells (DCs) in the tumor microenvironment. This expansion of DCs enhances the cross-presentation of tumor-associated antigens to CD8+ T cells, thereby boosting systemic antitumor immune responses. It is frequently studied in combination with immune checkpoint blockades, such as anti-CTLA-4, where it has demonstrated the ability to promote both prophylactic and therapeutic rejection of established tumors.

Other names

irradiated Flt3L-expressing B16-F10 tumor cell vaccineB16-Flt3L vaccineB-16-Flt3L vaccineB 16-Flt3L vaccineFl3vaxFl-3vaxFl 3vax